language_icon
EN
HI

Panacea Biotec Share price

PANACEABIO

368.55

12.05 (3.38%)
NSE
BSE
Last updated on 24 Apr, 2026 | 15:55 IST
Today's High

373.00

Today's Low

347.00

52 Week Low

292.40

52 Week High

581.90

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Panacea Biotec Chart

Panacea Biotec Share Key Metrics

Volume
1.77 L
Market Cap
2257.40 CR
LTQ@LTP
3@368.55
ATP
360.12
Var Margin
26.01 %
Circuit Range
285.2-427.8
Delivery %
51.09 %
Value
6.39 CR
ASM/GSM
No
Market Lot
1

Summary

Panacea Biotec share price stands at ₹368.55 at 24 Apr, 2026 | 15:55. The stock Panacea Biotec intraday movement has stayed between ₹347.00 and ₹373.00, while on a 52-week basis it has fluctuated from ₹292.40 to ₹581.90.
In terms of trading activity, Panacea Biotec has recorded a volume of 177387 shares. The Panacea Biotec has a market cap of ₹61250746. The stock’s Average Traded Price (ATP) stands at ₹36012, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 3, 36855.
The Panacea Biotec operates within a circuit range of ₹285.2-427.8 – ₹285.2-427.8, with a Value of ₹6.39 CR. The Delivery Percentage for the day is 51.09%. Additionally, Panacea Biotec currently falls under the No framework, and trades with a market lot size of 1.

Panacea Biotec Fundamentals

View More
P/E Ratio

0

P/B Ratio

2.68

Div. Yield

0

Sector P/E

64.34

Sector P/B

3.51

Sec. Div. Yield

0.57

Panacea Biotec Resistance and Support

Pivot 359.35

Resistance

First Resistance

366.4

Second Resistance

376.3

Third Resistance

383.35

Support

First Support

349.45

Second Support

342.4

Third Support

332.5

Panacea Biotec Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

72.48%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

1.6%

Domestic Institutional Investors

1.97%

Retail

23.96%

Others

-0.01%

Total Promoters
MAR '26
72.48%

Panacea Biotec Corporate Actions

DateAgenda
2026-02-11Quarterly Results
2025-11-14Quarterly Results
2025-08-14Quarterly Results
2025-05-30Audited Results & Dividend
2025-02-14Quarterly Results

Panacea Biotec News

Panacea Biotec Limited

Panacea Biotec Limited secured a ₹20.79 crore order from the Central Medical Services Society (CMSS) for supplying Diphtheria and Tetanus Vaccine (Td Vaccine). The supply will commence in September/October 2026 and conclude by November/December 2028.
Apr 11 2026 16:04:00

Panacea Biotec Limited

Panacea Biotec Limited secured a ₹20.79 crore order from the Central Medical Services Society (CMSS) for supplying Diphtheria and Tetanus Vaccine (Td Vaccine). The supply will commence in September/October 2026 and conclude by November/December 2028.
Apr 11 2026 16:04:00

Panacea Biotec Limited

Panacea Biotec received a Letter of Award worth ₹20.79 crore from the Central Medical Services Society. The contract is for the supply of Diphtheria and Tetanus Vaccine (Td Vaccine) for Adults and Adolescents, to be executed in tranches until November/December 2028.
Apr 11 2026 16:04:00

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order

Panacea Biotec secured a ₹20.79 crore Letter of Award from Central Medical Services Society (CMSS) for Diphtheria and Tetanus Vaccine supply. This domestic order will be supplied in tranches from October 2026 to December 2028.
Apr 11 2026 16:04:00

Panacea Biotec Ltd - 531349 - Receipt Of Awards From The Presiding Officer Of Industrial Tribunal, Mohali

Panacea Biotec received four awards from an Industrial Tribunal on March 19, 2026, concerning labor disputes with workmen, including back wages and reinstatement. The company plans to appeal the awards and believes there will be no material adverse financial impact.
Apr 10 2026 16:04:00

Panacea Biotec Limited

Panacea Biotec received a rectified DCIT assessment order on April 06, 2026, setting its tax liability for AY 2016-17 as Nil. This action nullifies the previous ~₹10.23 crore demand, correcting errors from the initial order and removing adverse financial impact.
Apr 07 2026 12:04:00

Panacea Biotec Limited

Panacea Biotec's tax liability of ~₹45.71 crore for Assessment Year 2015-16 has been nullified. The Income Tax Department issued a rectified assessment order, correcting errors from the prior demand.
Apr 07 2026 12:04:00

Panacea Biotec Ltd - 531349 - Receipt Of Rectified Assessment Order For AY 2016-17

Panacea Biotec's tax liability for AY 2016-17 has been determined as nil by the DCIT, reversing an earlier demand of ₹10.23 crore. This rectification corrected errors including double disallowances and omission of set-off for brought-forward losses.
Apr 07 2026 11:04:00

Panacea Biotec Ltd - 531349 - Receipt Of Rectified Assessment Order For AY 2015-16

Panacea Biotec's tax liability for Assessment Year 2015-16 has been resolved to Nil following a rectified assessment order from the DCIT. This nullifies the previous demand of ~₹45.71 crore.
Apr 07 2026 11:04:00

Panacea Biotec Limited

Panacea Biotec: Mukul Gupta ceased to be a Non-Executive Independent Director effective March 31, 2026. His cessation is due to the completion of his tenure on the board.
Apr 01 2026 10:04:00
Read More

About Panacea Biotec

NSE : 4055  
BSE : 531349  
ISIN : INE922B01023  

Panacea Biotec Ltd. was incorporated as a private limited company in the name and style of Panacea Drugs Private Ltd. on 2nd February 1984. Subsequently the Company became deemed Public limited Company u/s 43A(1 A) of the Companies Act 1956 w.e.f. 30.6.93. The shareholders of the Company in Extra Ordinary General Meeting passed a special resolution on 26.7.93 for deleting the Registration Clause from Articles of Association of the Company u/s 3(1) (iii) of the Companies Act 1956 and as such Company became full fledge public limited Company within the meaning of Section 3 (1) iv) of the Companies Act. Thereafterer the name of the Company hanged to Panacea Biotec Limited on 7th September 1993.The Company has been promoted by Mr. Sosh Kumar Jain who is a pharmacist having about 40 years of experience in the pharmaceutical industry.The Company started its operations in the year 1985 by identifying and importing a group of life saving drugs which were not available in the country for acute diseases like cancer haemophilia cardiac diseases infertility etc. These drugs were imported at an economical price andmade available through a distribution network of stockists all over the country. Having made a significant presence in the markat and after understanding the scope of the product and the latest trend in the medical field the Company made plans to set up its own manufacturing unit in 1989 and thereafter established a marketing team with an already existing distribution network for promotion of ethicalformulations.The promotors of the Company also happened to be the artners in another group company - Radicura Pharma engaged in he line of business of vaccines. Having established its marketing strength in both the group companies i.e. Vaccine Division as well as Pharma marketing the Company decided to make a single entity by merging both the unitsin the year 1992. The company is now utilising the strength of the products and marketing team of both the unit for better performance in the coming years. The Company continue to manufacture the Vaccines under Radicura Pharma with the after now functioning as a division of the Company.The Company started its Export promotion in 1991-92 when product registration in different countries was initiated. During 1993-94 the Comapny exported products worth Rs. 1.00 Crore.Presently the Company is engaged in 4 product lines of Pharmaceuticals. These are :- a) Vaccines b) Biologicals c) formulations d) Natural ProductsThe ethical formulations being promoted is on an all India basis. The Company has a significant presence in different therapeutic Groups. The company has a well established marketing network with dealers spread all over the country. The Company now proposes to expand the capacity of Vaccines Division along with an expansion in the capacities of capsules and suspensions.The company has achieved consistent improvement in rating terms of retail chemist sales out of top 200 Companies in India (Source: ORG Retail Sales Rating) out of companies promoting products ethically.Year March 1993 March 1994Rating 187 153Out of 200 200

Read More

Panacea Biotec Management

NamePosition
Ankit JainCompany Secretary and Compliance Officer
Rajesh JainChairman & Managing Director
View More

Panacea Biotec FAQs

The Buying Price of Panacea Biotec share is 368.55 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Panacea Biotec stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Panacea Biotec, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Panacea Biotec shares is 0. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Panacea Biotec shares is 2.68. Useful to assess the stock's value relative to its book value.

To assess Panacea Biotec’s valuation compare Sector P/E, P/B which are 64.34 & 3.51 with sector averages, along with growth rates and financial metrics.

The Market Cap of Panacea Biotec is 2257.40 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Panacea Biotec share price is 581.90 & 292.40. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Panacea Biotec belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost